Suchergebnisse - "Brown, Jennifer R"

PubPharm (447)

41

Idelalisib activates AKT via increased recruitment of PI3Kδ/PI3Kβ to BCR signalosome while reducing PDK1 in post-therapy CLL cells

enthalten in: Leukemia | 2022

von Mamidi, M. | Mahmud, H. | Maiti, G. | +6

42

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy : pooled analysis of 762 patients

enthalten in: Haematologica | 2022

von Brown, J. | Byrd, J. | Ghia, P. | +12

CommentIn: Haematologica. 2022 Jun 01;107(6):1489-1490. - PMID 34788988

43

Response to Comment on : "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients"

enthalten in: Haematologica | 2022

von Brown, J.

CommentOn: Haematologica. 2022 Jun 01;107(6):1489-1490. - PMID 34788988

44

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1) : results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

enthalten in: The Lancet. Haematology | 2022

von Bannerji, R. | Arnason, J. | Advani, R. | +16

CommentIn: Lancet Haematol. 2022 May;9(5):e314-e315. - PMID 35366964

45

Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia

enthalten in: British journal of haematology | 2022

von Gadi, D. | Griffith, A. | Wang, Z. | +7

46

Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

enthalten in: Haematologica | 2022

von Allan, J. | Pinilla-Ibarz, J. | Gladstone, D. | +16

47

A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia

enthalten in: Leukemia | 2022

von Gadi, D. | Griffith, A. | Tyekucheva, S. | +16

48

Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies

enthalten in: Molecular oncology | 2022

von Melvold, K. | Giliberto, M. | Karlsen, L. | +8

49

Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL : "What's Past Is Prologue" (Shakespeare)

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Mato, A. | Davids, M. | Sharman, J. | +25

50

Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome

enthalten in: Blood | 2022

von Davids, M. | Rogers, K. | Tyekucheva, S. | +12